First international TPS expert meeting in Berlin

The first international expert meeting on Transcranial Pulse Stimulation (TPS®) took place in Berlin on 29 April 2023. In the former Kaiserin-Augusta-Hospital, 30 neurologists and psychiatrists from 8 different countries met to discuss current TPS® topics related to the treatment of patients with Alzheimer’s disease and to share their knowledge about the application of the NEUROLITH® system.

Prof Dr Lars Wojtecki, head physician of the Department of Neurology and Neurorehabilitation at the Holy Spirit Hospital Kempen, the academic teaching hospital of the Heinrich Heine University Düsseldorf, explained the latest study situation and his clinical TPS® experience in the treatment of patients with symptoms of Alzheimer’s disease.

The lecture by Prof Dr Dr Ulrich Sprick, head physician of the outpatient services and day clinics of the psychiatric Alexius/Josef Hospital Neuss, focused among other things on the application of TPS® in the outpatient treatment of patients with Alzheimer’s disease.

Prof Dr Mehmet Zülküf Önal, NeuroUp Clinic in Ankara and Istanbul, also presented his clinical observations from several treatment centres in Turkey. Dr Ali Reza Günes, Alexius/Josef Hospital Neuss, and Prof Dr Oliver Seemann, head physician at the Breitenau Psychiatric Centre of the Schaffhausen Hospitals, provided further insights into their daily clinical routine with TPS®.

In addition to the exciting presentations of the key opinion leaders, valuable questions and ideas from research and practice around TPS® were discussed during the meeting. These point to increasing evidence on the efficacy and safety of TPS® in the treatment of patients with symptoms of Alzheimer’s disease and emphasised the importance of scientific and clinical research – also for other neurological indications such as depression, fatigue or Parkinson’s disease.

The meeting was initiated by Prof Dr Lars Wojtecki, who, as a study initiator at the University Hospital Düsseldorf, is planning a multicentre prospective data collection on TPS® treatment in patients with Alzheimer’s disease. This was followed by a smaller meeting to discuss the further planning of the study, which is to include 10 participating German centres, more than 100 planned patients and a follow-up of 12 months.

Further exciting events on the topic of TPS® will follow this year. We will report on them regularly.